Information Provided By:
Fly News Breaks for February 11, 2019
KMB, PG, CL
Feb 11, 2019 | 12:32 EDT
Exane BNP Paribas analyst Jeff Stent upgraded Colgate-Palmolive (CL) to Neutral from Underperform and raised his price target for the shares to $67 from $56. Investor interest in Colgate will continue to build with its organic sales growth trends set to improve and with a management change "seemingly close," Stent tells investors in a research note. The analyst also raised his price target for Procter & Gamble (PG) to $95 from $86 and keeps an Underperform rating on the name. The company's near-term organic growth has an "upside bias," but this is already reflect in the stock following the "recent meteoric re-rating," Stent contends. In taking his Home and Personal Care coverage to three stocks, the analyst today also initiated coverage of Kimberly-Clark (KMB) with an Outperform rating and $130 price target. Kimberly-Clark is Stent's preferred way to play the U.S. Home and Personal Care space. While the company faces structural challenges, "if ever there is a time to buy, it is now" as the input cost picture improves and industry pricing is "starting to kick in," he says.
News For CL;PG;KMB From the Last 2 Days
PG
Apr 22, 2024 | 09:00 EDT
Deutsche Bank lowered the firm's price target on Procter & Gamble to $171 from $172 and keeps a Buy rating on the shares following the fiscal Q3 report.
PG
Apr 22, 2024 | 08:33 EDT
Raymond James raised the firm's price target on Procter & Gamble to $178 from $175 and keeps an Outperform rating on the shares after fiscal Q3 EPS of $1.52 came in well above the firm's estimate and consensus. P&G continues to grow profitability ahead of peers even as top-line growth decelerates, notes the firm, which raised its FY24 EPS estimate to $6.56 from $6.44.
PG
Apr 22, 2024 | 08:01 EDT
Evercore ISI raised the firm's price target on Procter & Gamble to $177 from $175 and keeps an Outperform rating on the shares. While "understandably" the focus in the earnings call was on the drivers of sales slowing to 3%, comps considered, this 3% rate already marks a rebound versus prior Q2 on a two-year stack and three-year run rate basis, says the analyst, who adds that calendar 2025 Street expectations "strike us as conservative."